liafensine

Liafensine is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI), also known as a triple monoamine reuptake inhibitor. It was originally developed by Bristol Myers Squibb for the treatment of major depressive disorder and later investigated for treatment-resistant depression. Liafensine acts by inhibiting the reuptake of serotonin, norepinephrine, and dopamine in the brain, thereby increasing their extracellular concentrations. Recent development has been led by Denovo Biopharma using a biomarker-guided approach to identify patients most likely to respond to therapy[1][6][8]. In clinical trials, liafensine demonstrated efficacy comparable to established antidepressants but did not show superiority over them in earlier studies; however, recent biomarker-guided trials have shown significant improvement in depressive symptoms among DGM4-positive patients with treatment-resistant depression[7][10].

Brand names

Liafensine

Other names

liafensina